MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, targeting industrial safety applications in South America's mining sector. The company has appointed Chilean drug policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a strategic focus on Chile's mining industry, which employs more than 200,000 workers.
MindBio's technology analyzes voice patterns to detect intoxication or impairment without biological testing, positioning it as a scalable tool for workplace safety in mining and other high-risk industries. The platform is expected to begin deployment in industrial environments in 2026, with Chile's mining sector representing an early target market.
The company recently closed an upsized non-brokered private placement of up to $1.5 million to support commercialization activities. According to the press release, MindBio is a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection.
This development is important because it addresses a critical need in high-risk industries for non-invasive, scalable impairment detection. Traditional methods like biological testing can be time-consuming and intrusive, whereas voice analysis offers rapid, continuous screening. The focus on South America's mining sector, a significant economic driver, underscores the potential for widespread adoption.
For further information, the latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF.
MindBio Therapeutics Corp. is listed on the Canadian Securities Exchange (CSE: MBIO) and trades on the OTCQB Venture Market (OTCQB: MBQIF).
